Combined use of organo- and enzymic catalysis in three component couplings: Building blocks for bioactive molecule synthesis
Lead Research Organisation:
University of Leeds
Department Name: Sch of Chemistry
Abstract
The preparation of biological molecules, such as drugs and agrochemicals, generally involves many separate synthetic steps. At the end of each step, an intermediate is usually purified before functionalisation in the next step. To improve the efficiency of the construction of such molecules, the number of separate reactions and purifications would need to be reduced. This proposal will generate new methods which will allow more than one step to be performed in a single reaction vessel. This approach is broadly analogous to would involve the concatenation of several steps Nature: metabolic pathways involve the processing of reaction intermediate by compatible (enzyme) catalysts in a single reaction vessel (the cell). The products of the new methodology will be exploited in the synthesis of building blocks for preparation of biologically active molecules.
People |
ORCID iD |
Adam Nelson (Principal Investigator) | |
Alan Berry (Co-Investigator) |
Publications
Campeotto I
(2010)
Structural insights into substrate specificity in variants of N-acetylneuraminic Acid lyase produced by directed evolution.
in Journal of molecular biology
Kinnell A
(2012)
Development of an organo- and enzyme-catalysed one-pot, sequential three-component reaction
in Tetrahedron
Windle CL
(2014)
Engineering aldolases as biocatalysts.
in Current opinion in chemical biology
Description | IMI CHEM21 consortium |
Amount | € 1,200,000 (EUR) |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 09/2012 |
End | 09/2016 |
Description | AZ enzyme |
Organisation | AstraZeneca |
Department | Research and Development AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Development of enzymes for synthesis |
Collaborator Contribution | Supervison. Input to project |
Impact | A paper. |
Start Year | 2009 |
Description | GSK enzymes |
Organisation | GlaxoSmithKline (GSK) |
Country | Global |
Sector | Private |
PI Contribution | Development of chemically-modified enzymes |
Collaborator Contribution | Supervision. Input to project |
Impact | None to date |
Start Year | 2013 |